StrangeK. The end of “naive reductionism”: rise of systems biology or renaissance of physiology?Am J Physiol Cell Physiol.2005; 288(5): C968-74.
2.
LyonsAS, PetrucelliR. Medicine: An illustrated history.New York: Harry N. Abrams; 1987.
3.
FangFC, CasadevallA. reductionistic and holistic science.Infect Immun.2011; 79(4): 1401–4.
4.
HaninL. Why victory in the war on cancer remains elusive: biomedical hypotheses and mathematical models.Cancers.2011; 3: 340–67.
5.
Jackson NakazawaD. The autoimmune epidemic: bodies gone haywire in a world out of balance—and the cutting-edge science that promises hope.1st ed.New York: Touchstone; 2008.
6.
LaplaceP-S. Essai philosophique sur les probabilités, p.4: éd.Bachelier;1840.
7.
DescartesR. Discours de la méthode: pour bien conduire sa raison, et chercher la vérité dans les sciences (A discourse of the method for conducting oneself with reason, and searching for truth in the sciences),Vol Cinquième: éd. Cousin;1637: 142.
8.
VerduijnM, JagerKJ, ZoccaliC, DekkerFW. Genetic association studies: discovery of the genetic basis of renal disease.Nephron Clin Pract.2011; 119(3): c236-9.
9.
WoodsMO, YounghusbandHB, ParfreyPSThe genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease.Gut.Oct2010; 59(10): 1369–77.
10.
MollerCC, PollakMR, ReiserJ. The genetic basis of human glomerular disease.Adv Chronic Kidney Dis.2006; 13(2): 166–73.
11.
DayIN, GuD, GandertonRH, SpanakisE, YeS. Epidemiology and the genetic basis of disease.Int J Epidemiol.2001; 30(4): 661–7.
12.
PartridgeM. Oral cancer: 1. The genetic basis of the disease.Dent Update.2000; 27(5): 242–8.
13.
TsipourasP, SilvermanDI. The genetic basis of aortic disease. Marfan syndrome and beyond.Cardiol Clin.1999; 17(4): 683–96.
14.
TayA. Genetic basis of disease: studies of eicosanoids and some complex disease traits.Clin Sci (Lond).1996; 91(3): 264–6.
15.
JohnsonMC, PayneRM, GrantJW, StraussAW. The genetic basis of paediatric heart disease.Ann Med.Jun1995; 27(3): 289–300.
16.
ArnoldA. Genetic basis of endocrine disease 5. Molecular genetics of parathyroid gland neoplasia.J Clin Endocrinol Metab.Nov1993; 77(5): 1108–12.
17.
McPhaulMJ, MarcelliM, ZoppiS, GriffinJE, WilsonJD. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance.J Clin Endocrinol Metab.Jan1993; 76(1): 17–23.
18.
FaginJA. Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia.J Clin Endocrinol Metab.Dec1992; 75(6): 1398–1400.
19.
WadiaRS. Another genetic basis for vascular disease.Natl Med J India.1992; 5(2): 71–2.
20.
WhitePC, NewMI. Genetic basis of endocrine disease 2: congenital adrenal hyperplasia due to 21-hydroxylase deficiency.J Clin Endocrinol Metab.1992; 74(1): 6–11.
21.
TaylorSI, CamaA, AcciliDGenetic basis of endocrine disease. 1. Molecular genetics of insulin resistant diabetes mellitus.J Clin Endocrinol Metab.1991; 73(6): 1158–63.
22.
GrantDA. Genetic polymorphism of the alcohol metabolising enzymes as a basis for alcoholic liver disease.Br J Addict.1988; 83(11): 1255–9.
23.
KidsonC, ChenP. DNA damage, DNA repair and the genetic basis of Alzheimer's disease.Prog Brain Res.1986; 70: 291–301.
24.
ElenkovIJ, WilderRL, ChrousosGP, ViziES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system.Pharmacol Rev.2000; 52(4): 595–638.
25.
MadsenR, LundstedtT, TryggJ. Chemometrics in metabolomics-a review in human disease diagnosis.Anal Chim Acta.2010; 659(1-2): 23–33.
26.
SpratlinJL, SerkovaNJ, EckhardtSG. Clinical applications of metabolomics in oncology: a review.Clin Cancer Res.2009; 15(2): 431–40.
27.
WangH, TsoVK, SlupskyCM, FedorakRN. Metabolomics and detection of colorectal cancer in humans: a systematic review.Future Oncol.2010; 6(9): 1395–406.
28.
HeazellAE, BrownM, WortonSA, DunnWB. Review: The effects of oxygen on normal and pre-eclamptic placental tissue—insights from metabolomics.Placenta.2011; 32 Suppl 2:S119–24.
29.
GalvaoER, MartinsLM, IbiapinaJO, AndradeHM, MonteSJ. Breast cancer proteomics: a review for clinicians.J Cancer Res Clin Oncol.2011; 137(6): 915–25.
30.
BuczynskiMW, DumlaoDS, DennisEA. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology.J Lipid Res.2009; 50(6): 1015–38.
31.
SchifferE, MischakH, ZimmerliLU. Proteomics in gerontology: current applications and future aspects-a mini-review.Gerontology.2009; 55(2): 123–37.
32.
GastMC, SchellensJH, BeijnenJH. Clinical proteomics in breast cancer: a review.Breast Cancer Res Treat.2009; 116(1): 17–29.
33.
ConradDH, GoyetteJ, ThomasPS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening.J Gen Intern Med.2008; 23 Suppl 1:78–84.
34.
DrakeTA, PingP. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Proteomics approaches to the systems biology of cardiovascular diseases.J Lipid Res.2007; 48(1): 1–8.
PatelPS, TelangSD, RawalRM, ShahMH. A review of proteomics in cancer research.Asian Pac J Cancer Prev.Apr-Jun2005; 6(2): 113–117.
37.
IdekerT, GalitskiT, HoodL. A new approach to decoding life: systems biology.Annu Rev Genomics Hum Genet.2001; 2: 343–72.
38.
HoodL, RowenL, GalasDJ, AitchisonJD. Systems biology at the Institute for Systems Biology.Briefings in functional genomics and proteomics.2008; 7(4): 239–248.
39.
Von BertalanffyL. The history and status of general systems theory.Acad Manage J.1972; 15(4): 407–26.
40.
MillerJG. Living systems.New York: McGraw-Hill; 1978.
41.
Red'koVG, ProkhorovDV, BurtsevMB. Theory of functional systems, adaptive critics and neural networks.Paper presented at: Proceedings of International Joint Conference on Neural Networks, 2004; Budapest.
42.
MillerJG. Toward a general theory for the behavioral sciences.Am Psychol.1955; 10(9): 513–531.
43.
CapraF. The web of life: a new scientific understanding of living systems. 1st Anchor Books ed.New York: Anchor Books; 1996.
44.
TubbsS. A systems approach to small group interaction.11th ed.New York: McGraw-Hill Humanities/Social Sciences/Languages; 2011.
45.
ClaytonT, RadcliffN. Sustainability: a systems approach.1st ed: London: Routledge;1996.
46.
CapraF, PauliGA. Steering business toward sustainability.Tokyo; New York: United Nations University Press; 1995.
47.
DrydenGWJr., DeaciucI, ArteelG, McClainCJ. Clinical implications of oxidative stress and antioxidant therapy.Curr Gastroenterol Rep.2005; 7(4): 308–16.
48.
JamesSJ, RoseS, MelnykSCellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism.FASEB J.2009; 23(8): 2374–83.
49.
LeeDH, GrossMD, SteffesMW, JacobsDRJr. Is serum gamma-glutamyl-transferase a biomarker of xenobiotics, which are conjugated by glutathione?Arterioscler Thromb Vasc Biol.2008; 28(4): e26–8; author reply e29.
50.
MorinoK, PetersenKF, ShulmanGI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.Diabetes.2006; 55 Suppl 2:S9–15.
51.
DhanasekaranM, RenJ. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus.Curr Neurovasc Res.2005; 2(5): 447–59.
52.
AuffrayC, AdcockIM, ChungKF, DjukanovicR, PisonC, SterkPJ. An integrative systems biology approach to understanding pulmonary diseases.Chest.2010; 137(6): 1410–6.
53.
TaylorBS, VaramballyS, ChinnaiyanAM. A systems approach to model metastatic progression.Cancer Res.2006; 66(11): 5537–9.
54.
BarrenasF, ChavaliS, HolmeP, MobiniR, BensonM. Network properties of complex human disease genes identified through genome-wide association studies.PLoS One.2009; 4(11): e8090.
55.
BoscoA, McKennaKL, FirthMJ, SlyPD, HoltPG. A network modeling approach to analysis of the Th2 memory responses underlying human atopic disease.J Immunol.2009; 182(10): 6011–21.
56.
ChavaliS, BarrenasF, KanduriK, BensonM. Network properties of human disease genes with pleiotropic effects.BMC Syst Biol.2010; 4: 78.
57.
DudleyJT, ButteAJ. Identification of discriminating biomarkers for human disease using integrative network biology.Pac Symp Biocomput.2009: 27–38.
58.
GohKI, CusickME, ValleD, ChildsB, VidalM, BarabasiAL. The human disease network.Proc Natl Acad Sci U S A.2007; 104(21): 8685–90.
59.
JiangJQ, DressAW, ChenM. Towards prediction and prioritization of disease genes by the modularity of human phenome-genome assembled network.J Integr Bioinform.2010; 7(2).
60.
LeeDS, ParkJ, KayKA, ChristakisNA, OltvaiZN, BarabasiAL. The implications of human metabolic network topology for disease comorbidity.Proc Natl Acad Sci U S A.2008; 105(29): 9880–5.
61.
LoscalzoJ. Systems biology and personalized medicine: a network approach to human disease.Proc Am Thorac Soc.2011; 8(2): 196–8.
62.
ZanzoniA, Soler-LopezM, AloyP. A network medicine approach to human disease.FEBS Lett.2009; 583(11): 1759–65.
63.
ShahSP, RothA, GoyaRThe clonal and mutational evolution spectrum of primary triple-negative breast cancers.Nature.2012; 486(7403): 395–9.
64.
UrbachD, MooreJH. Mining the diseasome.BioData Min.2011; 4: 25.
65.
IakoubovaOA, RobertsonM, TongCHKIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study.Eur J Cardiovasc Prev Rehabil.2010; 17(4): 455–61.
66.
AssimesTL, HolmH, KathiresanSLack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies.J Am Coll Cardiol.2010; 56(19): 1552–63.
67.
MathewJ, NarayananP, SundaramRLack of association between Glu(298) asp polymorphism of endothelial nitric oxide synthase (eNOS) gene and coronary artery disease in Tamilian population.Indian Heart J.2008; 60(3): 223–7.
68.
TsantesAE, NikolopoulosGK, BagosPG, VaiopoulosG, TravlouA. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis.Int J Cardiol.2007; 118(2): 189–96.
69.
AngiolilloDJ, Fernandez-OrtizA, BernardoELack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.Thromb Res.2005; 116(6): 491–7.
70.
SchmoelzerI, RennerW, PaulweberBLack of association of the Glu298Asp polymorphism of endothelial nitric oxide synthase with manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian populations.Eur J Clin Invest.2003; 33(3): 191–8.
71.
SiguschHH, SurberR, LehmannMHLack of association between 27-bp repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease.Scand J Clin Lab Invest.2000; 60(3): 229–35.
72.
AndersonJL, MuhlesteinJB, HabashiJLack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.J Am Coll Cardiol.1999; 34(6): 1778–83.
73.
GargUC, ArnettDK, FolsomAR, ProvinceMA, WilliamsRR, EckfeldtJH. Lack of association between platelet glycoprotein IIb/IIIa receptor PlA polymorphism and coronary artery disease or carotid intima-media thickness.Thromb Res.1998; 89(2): 85–9.
74.
FujimuraT, YokotaM, KatoSLack of association of angiotensin converting enzyme gene polymorphism or serum enzyme activity with coronary artery disease in Japanese subjects.Am J Hypertens.1997; 10(12 Pt 1):1384–90.
75.
HalanychKM, GoertzenLR. Grand challenges in organismal biology: The need to develop both theory and resources.Integr Comp Biol.2009; 49(5): 475–9.
76.
SchwenkK, PadillaDK, BakkenGS, FullRJ. Grand challenges in organismal biology.Integr Comp Biol.2009; 49(1): 7–14.
77.
LiptonB. The biology of belief: unleashing the power of consciousness, matter, & miracles. 13 ed.New York: Hay House; 2011.
78.
DuraffourdC, LaprazJC. Traite de Phytotherapie Clinique: Medicine et Endobiogenie. Masson ed.Paris: Masson; 2002.
79.
RaisonCL, MillerAH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders.Am J Psychiatry.2003; 160(9): 1554–65.
80.
ChiamK, TilleyWD, ButlerLM, Bianco-MiottoT. The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers.Biochim Biophys Acta.2009; 1795(2): 104–9.
81.
GerhardI, WaibelS, DanielV, RunnebaumB. Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages.Hum Reprod Update.1998; 4(3): 301–9.
82.
AtkinsonSA. Vitamin D status and bone biomarkers in childhood cancer.Pediatr Blood Cancer.2008; 50(2 Suppl):479–82; discussion 486.
83.
Chlebna-SokolD, RusinskaA. Serum insulin/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis.Endocr Regul.2001; 35(4): 201–8.
84.
DelmasPD, ChatelainP, MalavalL, BonneG. Serum bone GLA-protein in growth hormone deficient children.J Bone Miner Res.1986; 1(4): 333–8.
85.
NimptschK, HailerS, RohrmannS, GedrichK, WolframG, LinseisenJ. Determinants and correlates of serum undercarboxylated osteocalcin.Ann Nutr Metab.2007; 51(6): 563–70.
86.
TarleM. Plasma osteocalcin values and related hormonal parameters in patients subjected to a variety of prostate anticancer agents.Urol Res.1991; 19(1): 39–44.
87.
VietriMT, SessaM, PillaPSerum osteocalcin and parathyroid hormone in healthy children assessed with two new automated assays.J Pediatr Endocrinol Metab.2006; 19(12): 1413–9.
88.
BanuKS, AruldhasMM. Sex steroids regulate TSH-induced thyroid growth during sexual maturation in Wistar rats.Exp Clin Endocrinol Diabetes.2002; 110(1): 37–42.
89.
CuencaE, SerranoMI, Gibert-RaholaJ, GalianaJ. Enhancement of noradrenaline responses by thyrotropine-releasing hormone.J Pharm Pharmacol.1975; 27(3): 199–200.
90.
GidronY, RonsonA. Psychosocial factors, biological mediators, and cancer prognosis: a new look at an old story.Curr Opin Oncol.2008; 20(4): 386–92.
91.
GrimmY, ReichlinS. Thyrotropin releasing hormone (TRH): neurotransmitter regulation of secretion by mouse hypothalamic tissue in vitro.Endocrinology.1973; 93(3): 626–31.
92.
MorleyJE. Extrahypothalamic thyrotropin releasing hormone (TRH) - its distribution and its functions.Life Sci.Oct 291979; 25(18): 1539–1550.
93.
MorleyJE, KleinC, KalkWJPituitary responsiveness to thyrotropin releasing hormone in insulin-dependent diabetes mellitus.Horm Metab Res.1978; 10(3): 231–7.
94.
MortimerCH, BesserGM, McNeillyAS, TunbridgeWM, Gomez-PanA, HallR. Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH FSH-RH, TRH and hypoglycaemia alone and in combination.Clin Endocrinol (Oxf).Oct1973; 2(4): 317–26.
95.
SekulicM, Sosic-JurjevicB, FilipovicB, Manojlovic-StojanoskiM, MilosevicV. Immunoreactive TSH cells in juvenile and peripubertal rats after estradiol and human chorionic gonadotropin treatment.Acta Histochem.2006; 108(2): 117–23.
96.
ShahN, EvansWS, VeldhuisJD. Actions of estrogen on pulsatile, nyctohemeral, and entropic modes of growth hormone secretion.Am J Physiol.1999; 276(5 Pt 2):R1351–8.
97.
JoostenKF, de KleijnED, WesterterpMEndocrine and metabolic responses in children with meningoccocal sepsis: striking differences between survivors and nonsurvivors.J Clin Endocrinol Metab.2000; 85(10): 3746–53.
98.
GoetersC, MertesN, TackeJRepeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Effect on metabolic and hormonal patterns.Ann Surg.1995; 222(5): 646–53.
99.
RadettiG, PaganiniC, GentiliL, BarbinF, PasquinoB, ZachmannM. Altered adrenal and thyroid function in children with insulin-dependent diabetes mellitus.Acta Diabetol.1994; 31(3): 138–40.
100.
BugarestiJM, TatorCH, SilverbergJDChanges in thyroid hormones, thyroid stimulating hormone and cortisol in acute spinal cord injury.Paraplegia.1992; 30(6): 401–9.
101.
KjellmanBF, LjunggrenJG, Beck-FriisJ, WetterbergL. Reverse T3 levels in affective disorders.Psychiatry Res.1983; 10(1): 1–9.
102.
KahanaL, KeidarS, SheinfeldM, PalantA. Endogenous cortisol and thyroid hormone levels in patients with acute myocardial infarction.Clin Endocrinol (Oxf).1983; 19(1): 131–9.
103.
KoonoN. Reciprocal changes in serum concentrations of triiodothyronine and reverse triiodothyronine between summer and winter in normal adult men.Endocrinol Jpn.1980; 27(4): 471–6.
104.
BanosC, TakoJ, SalamonF, GyorgyiS, CzikkelyR. Effect of ACTH-stimulated glucocorticoid hypersecretion on the serum concentrations of thyroxine-binding globulin, thyroxine, triiodothyronine, reverse triiodothyronine and on the TSH-response to TRH.Acta Med Acad Sci Hung.1979; 36(4): 381–94.
105.
BoomershineCS. A comprehensive evaluation of standardized assessment tools in the diagnosis of fibromyalgia and in the assessment of fibromyalgia severity.Pain Res Treat.2011; 2012: 653714.
106.
SimonsickEM, NewmanAB, FerrucciLSubclinical hypothyroidism and functional mobility in older adults.Arch Intern Med.2009; 169(21): 2011–7.
107.
BaekJH, ChungPW, KimYBFavorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients.Endocr J.2009; 57(1): 23–9.
108.
AkcakoyunM, KayaH, KarginRAbnormal left ventricular longitudinal functional reserve assessed by exercise pulsed wave tissue Doppler imaging in patients with subclinical hypothyroidism.J Clin Endocrinol Metab.2009; 94(8): 2979–83.
109.
SellMA, SchottM, TharandtL, CissewskiK, ScherbaumWA, WillenbergHS. Functional central hypothyroidism in the elderly.Aging Clin Exp Res.2008; 20(3): 207–10.
110.
TramoniE, Aubert-KhalfaS, GuyeM, RanjevaJP, FelicianO, CeccaldiM. Hypo-retrieval and hyper-suppression mechanisms in functional amnesia.Neuropsychologia.2009; 47(3): 611–24.
111.
VerslypeC. Evaluation of abnormal liver-enzyme results in asymptomatic patients.Acta Clin Belg.2004; 59(5): 285–9.
112.
PrattDS, KaplanMM. Evaluation of abnormal liver-enzyme results in asymptomatic patients.N Engl J Med.Apr 272000; 342(17): 1266–71.
113.
ThealRM, ScottK. Evaluating asymptomatic patients with abnormal liver function test results.Am Fam Physician.1996; 53(6): 2111–9.
114.
AltmanDG, BlandJM. Diagnostic tests. 1: Sensitivity and specificity.BMJ.1994; 308(6943): 1552.
115.
ColglazierCL, SutejPG. Laboratory testing in the rheumatic diseases: a practical review.South Med J.2005; 98(2): 185–91.
116.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum.1997; 40(9): 1725.
117.
Biomarkers Definitions Working Group.Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.Clin Pharmacol Ther.2001; 69(3): 89–95.
118.
VasanRS. Biomarkers of cardiovascular disease: molecular basis and practical considerations.Circulation.2006; 113(19): 2335–62.
119.
ColeM, RutherfordRB, SmithFO. Experimental ammonia encephalopathy in the primate.Trans Am Neurol Assoc.1970; 95: 82–5.
120.
ColeM, RutherfordRB, SmithFO. Experimental ammonia encephalopathy in the primate.Arch Neurol.1972; 26(2): 130–6.
121.
BernalW, HallC, KarvellasCJ, AuzingerG, SizerE, WendonJ. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure.Hepatology.2007; 46(6): 1844–52.
122.
HaussingerD, SchliessF. Pathogenetic mechanisms of hepatic encephalopathy.Gut.2008; 57(8): 1156–65.
123.
LeeDH, LimJS, SongK, BooY, JacobsDRJr. Graded associations of blood lead and urinary cadmium concentrations with oxidative-stress-related markers in the U.S. population: results from the third National Health and Nutrition Examination Survey.Environ Health Perspect.2006; 114(3): 350–4.
124.
ShiM, GozalE, ChoyHA, FormanHJ. Extracellular glutathione and gamma-glutamyl transpeptidase prevent H2O2-induced injury by 2,3-dimethoxy-1,4-naphthoquinone.Free Radic Biol Med.1993; 15(1): 57–67.
125.
LeeDH, JacobsDRJr. Association between serum concentrations of persistent organic pollutants and gamma glutamyltransferase: results from the National Health and Examination Survey 1999-2002.Clin Chem.2006; 52(9): 1825–7.
126.
LeeDH, SteffesMW, JacobsDRJr. Can persistent organic pollutants explain the association between serum gamma-glutamyltransferase and type 2 diabetes?Diabetologia.2008; 51(3): 402–7.
127.
LeeDH, SilventoinenK, JacobsDRJr., JousilahtiP, TuomiletoJ. gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women.J Clin Endocrinol Metab.2004; 89(11): 5410–4.
128.
NemesZ, DevreeseB, SteinertPM, Van BeeumenJ, FesusL. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles.FASEB J.2004; 18(10): 1135–7.
129.
YatesCM, ButterworthJ, GordonA. gamma-Glutamyl transpeptidase in dementia.Neurobiol Aging.1989; 10(1): 107–8.
130.
ButterworthJ, YatesCM, ReynoldsGP. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases.J Neurol Sci.1985; 67(2): 161–71.
131.
LoombaR, RaoF, ZhangLGenetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins.Gastroenterology.2010; 139(3): 836–45, 845 e831.
132.
BidelS, SilventoinenK, HuG, LeeDH, KaprioJ, TuomilehtoJ. Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes.Eur J Clin Nutr.2008; 62(2): 178–85.
133.
LeeD, Jacobs JrDR, GrossMGamma-Glutamyltransferase is a predictor of incident diabetes and hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.Clin Chem.2003; 49(8): 1358–66.
134.
LeeDH, HaMH, KimJHGamma-glutamyltransferase and diabetes-a 4 year follow-up study.Diabetologia.Mar2003; 46(3): 359–364.
135.
LeeDH, JacobsDRJr, GrossM, SteffesM. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.Clin Chem.Jul2005; 51(7): 1185–1191.
136.
LimJS, LeeDH, ParkJY, JinSH, JacobsDRJr. A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey.Clin Chem.2007; 53(6): 1092–1098.
137.
ShinJY, HwangJH, JeongJY[The association of central obesity with type 2 diabetes among Koreans according to the serum gamma-glutamyl-transferase level: Korean genome and epidemiology study].J Prev Med Public Health.Nov2009; 42(6): 386–391.
138.
SongSH, KwakIS, KimYJCan gamma-glutamyltransferase be an additional marker of arterial stiffness? Circ J.Nov2007; 71(11): 1715–20.
139.
TargherG, ZoppiniG, LippiG, GuidiGC, MuggeoM. Effect of serum gam-ma-glutamyltransferase and obesity on the risk of dyslipidemia and poor glycemic control in type 2 diabetic patients: cross-sectional findings from the Verona Diabetes Study.Clin Chem.2007; 53(10): 1867–69; author reply 1869-70.
140.
KawamotoR, KoharaK, TabaraY, MikiT, OtsukaN. Serum gamma-glutamyl transferase levels are associated with metabolic syndrome in community-dwelling individuals.J Atheroscler Thromb.2009; 16(4): 355–62.
141.
HwangJH, ShinJY, ChunBAssociation between gamma-glutamyl-transferase and hypertension incidence in rural prehypertensive adults.J Prev Med Public Health.2010; 43(1): 18–25. [Korean.]
142.
LeeDH, HaMH, KimJR, GrossM, JacobsDRJr. Gamma-glutamyltransferase, alcohol, and blood pressure. A four-year follow-up study.Ann Epidemiol.2002; 12(2): 90–6.
143.
LeeDH, HaMH, KimKY, JinDG, JacobsDRJr. Gamma-glutamyltransferase: an effect modifier in the association between age and hypertension in a 4-year follow-up study.J Hum Hypertens.2004; 18(11): 803–7.
144.
KotaniK, ShimohiroH, AdachiS, SakaneN. The association between an increased level of gamma-glutamyl transferase and systolic blood pressure in diabetic subjects.Tohoku J Exp Med.2008; 214(4): 321–5.
145.
KotaniK, ShimohiroH, AdachiS, SakaneN. Changes in serum gamma-glutamyl transferase and blood pressure levels in subjects with normal blood pressure and prehypertension.Clin Chim Acta.2008; 389(1-2): 189–90.
146.
YamadaY, IkaiE, TsuritaniI, IshizakiM, HondaR, IshidaM. The relationship between serum gamma-glutamyl transpeptidase levels and hypertension: common in drinkers and nondrinkers.Hypertens Res.1995; 18(4): 295–301.
147.
MiuraK, NakagawaH, NakamuraHSerum gamma-glutamyl transferase level in predicting hypertension among male drinkers.J Hum Hypertens.1994; 8(6): 445–9.
148.
IkaiE, NoborizakaY, TsuritaniI, HondaR, IshizakiM, YamadaY. Serum gam-ma-glutamyl transpeptidase levels and hypertension in non-drinkers: a possible role of fatty liver in the pathogenesis of obesity related hypertension.Obes Res.1993; 1(6): 469–74.
149.
YamadaY, IshizakiM, KidoTAlcohol, high blood pressure, and serum gamma-glutamyl transpeptidase level.Hypertension.1991; 18(6): 819–26.
150.
YamadaY, IshizakiM, KidoT, HondaR, TsuritaniI, YamayaH. Relationship between serum gamma-glutamyl transpeptidase activity and blood pressure in middle-aged male and female non-drinkers.J Hum Hypertens.1990; 4(6): 609–614.
151.
HenningsenNC, OhlssonO, MattiassonI, TrellE, KristenssonH, HoodB. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males.Acta Med Scand.1980; 207(4): 245–51.
152.
AblinRJ. Prostate-specific antigen: chronology of its identification.Oncology (Williston Park).1998; 12(7): 1016.
153.
AblinRJ. A retrospective and prospective overview of prostate-specific antigen.J Cancer Res Clin Oncol.1997; 123(11-12): 583–94.
154.
GuptaS, CammAJ. Chlamydia pneumoniae and coronary heart disease.BMJ.1997; 314(7097): 1778–9.
155.
OttoSJ, MossSM, MaattanenLPSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.Eur J Cancer.2010; 46(17): 3053–60.
156.
GuraT. Chlamydia protein linked to heart disease.Science.1999; 283(5406): 1238–9.
157.
MendallMA, CarringtonD, StrachanDChlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease.J Infect.1995; 30(2): 121–8.
158.
MiettinenH, LehtoS, SaikkuPAssociation of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland.Eur Heart J.1996; 17(5): 682–8.
159.
MiyashitaN, ToyotaE, SawayamaT, MatsushimaT. An association of an antibody against Chlamydia pneumoniae and coronary heart disease observed in Japan.Eur Heart J.1998; 19(6): 971.
160.
NaiduBR, NgeowYF, KannanPEvidence of Chlamydia pneumoniae infection obtained by the polymerase chain reaction (PCR) in patients with acute myocardial infarction and coronary heart disease.J Infect.1997; 35(2): 199–200.
161.
NietoFJ, FolsomAR, SorliePD, GraystonJT, WangSP, ChamblessLE. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study.Am J Epidemiol.1999; 150(2): 149–56.
162.
SaikkuP, LeinonenM, MattilaKSerological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.Lancet.1988; 2(8618): 983–6.
163.
SaikkuP, LeinonenM, TenkanenLChronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.Ann Intern Med.1992; 116(4): 273–8.
164.
Taylor-RobinsonD, ThomasBJ. Antibodies to cytomegalovirus or Chlamydia pneumoniae and coronary heart disease.Lancet.1998; 351(9096): 142; author reply 143.
165.
QuinnTC. Does Chlamydia pneumoniae cause coronary heart disease?Curr Opin Infect Dis.1998; 11(3): 301–7.
166.
SongZ, BrassardP, BrophyJM. A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases.Can J Cardiol.2008; 24(5): 391–5.
167.
StassenFR, VainasT, BruggemanCA. Infection and atherosclerosis. An alternative view on an outdated hypothesis.Pharmacol Rep.2008; 60(1): 85–92.
168.
JafarzadehA, Esmaeeli-NadimiA, ShariatiM. High sensitivity C-reactive protein and immunoglobulin G against Chlamydia pneumoniae and chlamydial heat shock protein-60 in ischemic heart disease.Iran J Immunol.2008; 5(1): 51–6.
169.
AndersonJL, MayHT, HorneBDRelation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population.Am J Cardiol.2010; 106(7): 963–8.
170.
JuddSE, TangprichaV. Vitamin D deficiency and risk for cardiovascular disease.Am J Med Sci.2009; 338(1): 40–4.
171.
WangTJ, PencinaMJ, BoothSLVitamin D deficiency and risk of cardiovascular disease.Circulation.2008; 117(4): 50311.
172.
SchleithoffSS, ZittermannA, TenderichG, BertholdHK, StehleP, KoerferR. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial.Am J Clin Nutr.2006; 83(4): 754–9.
173.
PollackMM, PatelKM, RuttimannUE. PRISM III: an updated Pediatric Risk of Mortality score.Crit Care Med.1996; 24(5): 743–52.
174.
ZimmermanJE, KramerAA, McNairDS, MalilaFM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients.Crit Care Med.May2006; 34(5): 1297–1310.
175.
ChenBS, WangYC, WuWS, LiWH. A new measure of the robustness of biochemical networks.Bioinformatics.2005; 21(11): 2698–705.
176.
HwangD, RustAG, RamseySA data integration methodology for systems biology.Proc Natl Acad Sci U S A.2005; 102(48): 17296–301.
177.
HwangD, SmithJJ, LeslieDMA data integration methodology for systems biology: experimental verification.Proc Natl Acad Sci U S A.2005; 102(48): 17302–17307.
178.
BainBJ, EnglandJM. Normal haematological values: sex difference in neutrophil count.Br Med J.1975; 1(5953): 306–9.
179.
MolloyEJ, O'NeillAJ, GranthamJJSex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone.Blood.2003; 102(7): 2653–9.
180.
BainB, SeedM, GodslandI. Normal values for peripheral blood white cell counts in women of four different ethnic origins.J Clin Pathol.1984; 37(2): 188–93.
181.
BainBJ. Ethnic and sex differences in the total and differential white cell count and platelet count.J Clin Pathol.1996; 49(8): 664–6.
182.
ChanPC, HayesL, BainBJ. A comparison of the white cell counts of cord blood from babies of different ethnic origins.Ann Trop Paediatr.1985; 5(3): 153–5.
183.
DaughadayWH, WilliamsRH, DalandGA. The effect of endocrinopathies on the blood.Blood.1948; 3(12): 1342–66.
184.
CarryerHM, BerkmanJM, MasonHL. Relative lymphocytosis in anorexia nervosa.Proc Staff Meet Mayo Clin.1959; 34: 426–32.
185.
Le MarquandHS, TozerFH. Fragilitas ossium in a family showing both thickening and rarefaction of bones, relative lymphocytosis and raised serum phosphatase with absence of blue sclerotics and otosclerosis.Proc R Soc Med.1935; 28(12): 1640–1.
186.
MenkinV. Relative lymphocytosis in hyperthyroidism.Arch Intern Med.1928; 42: 419–24.
187.
GardnerFH, PringleJCJr. Androgens and erythropoiesis. I. Preliminary clinical observations.Arch Intern Med.1961; 107: 846–62.
188.
NaetsJP, WittekM. The mechanism of action of androgens on erythropoiesis.Minerva Nucl.1965; 9(5): 281–4.
189.
GardnerFH, NathanDG. Androgens and erythropoiesis. 3. Further evaluation of testosterone treatment of myelofibrosis.N Engl J Med.1966; 274(8): 420–6.
190.
NaetsJP, WittekM. Mechanism of action of androgens on erythropoiesis.Am J Physiol.1966; 210(2): 315–20.
191.
FisherJW, SamuelsAI, MalgorLA. Androgens and erythropoiesis.Isr J Med Sci.1971; 7(7): 892–900.
192.
GardnerFH, GorsheinD. Regulation of erythropoiesis by androgens.Trans Am Clin Climatol Assoc.1973; 84: 60–70.
193.
EvensRP, AmersonAB. Androgens and erythropoiesis.J Clin Pharmacol.1974; 14(2): 94–101.
194.
CruickshankJM, MorrisR, ButtWR, CrookeAC. The relationship of total and differential leukocyte counts with urinary oestrogen and plasma cortisol levels.J Obstet Gynaecol Br Commonw.1970; 77(7): 634–9.
195.
CruickshankJM, MorrisR, ButtWR, CorkerCS. Inter-relationships between levels of plasma oestradiol, urinary total oestrogens and blood haemoglobin and neutrophil counts.J Obstet Gynaecol Br Commonw.1972; 79(5): 450–4.
196.
Riedel-BaimaB, RiedelA. Female pattern hair loss may be triggered by low oestrogen to androgen ratio.Endocr Regul.2008; 42(1): 13–6.
197.
ChangRJ, KatzSE. Diagnosis of polycystic ovary syndrome.Endocrinol Metab Clin North Am.1999; 28(2): 397–408.
RamanJD, SchlegelPN. Aromatase inhibitors for male infertility.J Urol.2002; 167(2 Pt 1):624–9.
200.
FejesI, KoloszarS, ZavaczkiZ, DaruJ, SzollosiJ, PalA. Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients.Arch Androl.2006; 52(2): 97–102.
201.
FaersteinE, SzkloM, RosensheinN. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking.Am J Epidemiol.2001; 153(1): 1–10.
202.
FarbA, BurkeAP, TangALCoronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death.Circulation.1996; 93(7): 1354–63.
203.
ShimomuraK, MandaT, MukumotoS, KobayashiK, NakanoK, MoriJ. Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity.Int J Cancer.1988; 41(2): 243–7.
204.
YacoubD, HachemA, TheoretJF, GillisMA, MouradW, MerhiY. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway.Arterioscler Thromb Vasc Biol.2010; 30(12): 2424–33.
205.
OlmarkerK, RydevikB. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica.Spine (Phila, Pa 1976).2001; 26(8): 863–9.
206.
OhtsuH. Progress in allergy signal research on mast cells: the role of hista-mine in immunological and cardiovascular disease and the transporting system of histamine in the cell.J Pharmacol Sci.2008; 106(3): 347–53.
207.
OzbenB, ErdoganO. The role of inflammation and allergy in acute coronary syndromes.Inflamm Allergy Drug Targets.Sep2008; 7(3): 136–144.
WinklerUH. Effects of androgens on haemostasis.Maturitas.Jul1996; 24(3): 147–55.
213.
HalushkaPV, MasudaA, MatsudaK. The Gordon Wilson Lecture. Regulation of thromboxane A2 receptors by testosterone: implications for steroid abuse and cardiovascular disease.Trans Am Clin Climatol Assoc.1994; 105: 95–103.
214.
NohJY, LimKM, BaeONProcoagulant and prothrombotic activation of human erythrocytes by phosphatidic acid.Am J Physiol Heart Circ Physiol.2010; 299(2): H347-55.
215.
SantosMT, VallesJ, LagoAResidual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease.J Thromb Haemost.2008; 6(4): 615–21.
216.
VallesJ, SantosMT, AznarJErythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity.Circulation.1998; 97(4): 350–5.
217.
SantosMT, VallesJ, AznarJ, MarcusAJ, BroekmanMJ, SafierLB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin.Circulation.1997; 95(1): 63–8.